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abstract: The discrete regulation of vascular tone in the human uterine and placental circulations is a key determinant of appropriate uter-
oplacental blood perfusion and pregnancy success. Humoral factors such as estrogen, which increases in the placenta and maternal circulation
throughout human pregnancy, may regulate these vascular beds as studies of animal arteries have shown that 17b-estradiol, or agonists of estro-
gen receptors (ER), can exert acute vasodilatory actions. The aim of this study was to compare how acute exposure to ER-specific agonists, and
17b-estradiol, altered human placental and uterine arterial tone in vitro. Uterine and placental arterieswere isolated frombiopsies obtained from
womenwith uncomplicated pregnancy delivering a singleton infant at term. Vessels weremounted on awiremyograph, exposed to the thromb-
oxane receptor agonist U46619 (1026 M), and then incubated with incremental doses (5 min, 0.03–30 mM) of either 17b-estradiol or agonists
specific for the ERs ERa (PPT), ERb (DPN) or the G-protein-coupled estrogen receptor GPER-1 (G1). ERa and ERb mRNA expression was
assessed. 17b-estradiol, PPT andDPNeach relaxedmyometrial arteries (P, 0.05) in amanner thatwas partly endothelium-dependent. In con-
trast, 17b-estradiol or DPN relaxed placental arteries (maximum relaxation to 42+1.1 or 47.6+6.53% of preconstriction, respectively) to a
lesser extent than myometrial arteries (to 0.03+ 0.03 or 8.0+ 1.0%) and in an endothelial-independent manner whereas PPT was without
effect. G1 exposure did not inhibit the constriction of myometrial nor placenta arteries. mRNA expression of ERa and ERbwas greater in myo-
metrial arteries thanplacental arteries. ER-specific agonists, and17b-estradiol, differentiallymodulate the toneof uterine versus placental arteries
highlighting that estrogen may regulate human uteroplacental blood flow in a tissue-specific manner.
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Introduction
A key determinant of appropriate fetal growth during human pregnancy
is the transfer across the placental epithelium of oxygen and nutrients
between the uterine and fetal circulations. As the two circulations are
separate physical entities—blood from the maternal uterine circulation
that traverses through the lumenof terminal open-ended spiral arterioles
is directed towards the syncytial surface of the placenta but does not
come in to direct contact with the enclosed fetoplacental circulatory
flow—then materno-fetal nutrient exchange will be influenced by
changes in either the uterine or placental vasculatures. This makes it im-
portant to understand how the blood vessels from each circulation
respond to physiological vasoactive factors. The placenta lacks auto-
nomic innervations (Myatt, 1992), which suggests that factors within
the local environment may be crucial for this purpose.
Estrogen may be one such modulator of uteroplacental vascular func-
tion. Estrogen’s effect on vascular tone has been documented in many
experimental and clinical contexts but not in relation to human preg-
nancy. Estrogen action via two receptors, ERa (also known as ESR1)
and ERb (also known as ESR2), classically initiates transcriptional
changes (Miller and Duckles, 2008). However, acute vasodilatory
actions of estrogen have pointed to non-genomic actions of ERa and
ERb. These may be mediated via endothelial-dependent and/or
-independent mechanisms (Shaw et al., 2000; Hisamoto and Bender,
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2005) with the former involving regulation of nitric oxide (NO) bioavail-
ability. Interestingly, a transmembrane G-protein-coupled receptor,
GPER-1 (also known as GPR30), has also been identified as an ER
capable of mediating rapid non-genomic signalling (Revankar and Pross-
nitz, 2005; Feldman and Gros, 2011) and it is of interest to unravel
whether estrogenic vasoactive actions may be mediated, in part or
wholly, via activation of this receptor.
In sheep in vivo, the uterine circulation exhibits a rapid vasodilatory
response to 17b-estradiol administration (Pastore et al., 2012). Such
actions may in part reflect activation of endothelial NO synthase
(NOS; Chen et al., 2004) and in rat uterine arteries isolated from non-
pregnant rats, but not those from late pregnant rats, 17b-estradiol-
mediated relaxations were partly blunted by NOS inhibition (Scott
et al., 2007). The involvement of ERs in these actions is a matter of
considerable debate. Certainly, reports of variations in the relative
abundance of mRNA encoding ERa or ERb in uterine endothelial cells
(Critchley et al., 2001; Liao et al., 2005; Pastore et al., 2012) points to
the possibility of receptor-specific estrogenic responses in the uterine
circulation. In comparison to these data, however, it is striking that
there is little information about the estrogenic effects on placental blood
vessels. The placenta is an important source of estrogen, evinced by the
substantial increase in maternal plasma level (You et al., 2006) and the
fetal adrenal gland contributes to estrogen within the placental circula-
tion (Smith et al., 2009). Thus, locally derived and/or locally acting estro-
gen maymodulate the vasoreactivity of the human uterine and placental
circulations. Of note, it has been suggested that the endothelium of
human fetoplacental blood vessels express ERb protein but that ERa is
absent or expressed at much less levels (Su et al., 2007, 2009).
The availability of agonists specific for ERa (PPT: (4,4′,4′′-(4-propyl-
[1H]-pyrazole-1,3,5-triyl) tris-phenol)), ERb (DPN: (2,3-bis(4-
hydroxyphenol)-propionitrile)), or GPER-1 (G1) has enabled mapping
of the non-genomic vasodilatory actions resulting from stimulation of
the different ERs across many vascular beds (Montgomery et al., 2003;
Hass et al., 2009; Feldman and Gros, 2011). However, a direct compari-
son of the acute estrogenic influences on arteries isolated from two
human vasculatures, and from patients with no medical complications,
has not been examined.
Therefore, we have investigated the effect of 17b-estradiol and
ER-specific agonistson the toneof humanplacental anduterine (myome-
trial) arteries isolated from biopsies of normal pregnant women with no
underlying pathophysiology. Our data point to a new understanding of
human uteroplacental vascular regulation by reporting that estrogen reg-
ulates the tone of arteries isolated from these circulations in ER- and
tissue-specific manners. This also alerts us to the possibility that varia-
tions in estrogenic responsiveness may exist across other human arterial
tissues.
Materials andMethods
Chemicals and solutions
ERagonistswerepurchased fromR&Dsystems (UK); other chemicals, unless
stated, were from Sigma (UK) or VWR (UK).
Sample collection and tissue microdissection
The study was approved by Local Research Ethics Committees and tissue
collected following written, informed consent from women with
uncomplicated, singleton term pregnancies (38–42weeks gestation). Arter-
ieswere dissected as described previously (Corcoran et al., 2012). Chorionic
plate arteries (diameter 284+18 mm) were dissected from placental biop-
sies obtained within 30 min of vaginal or elective Caesarean (not in labour)
delivery and placed directly into ice-cold tissue collection buffer ((TCB);
modified Krebs solution 2154 mM NaCl/5.4 mM KCl/1.2 mM MgSO4 .
7H2O/10 mM MOPS/5.5 mM glucose/1.6 mM CaCl2 . 2H2O; pH 7.4).
Myometrial arteries (diameter 209+23 mm) were obtained from biopsies
(1 cm3) taken at the time of Caesarean section from the upper segment
of the uterine incision and placed into ice-cold TCB.
Myography experiments and analysis
Four segments from each artery were mounted onto a wire myograph
(610M; Danish Myotechnologies, Denmark). After a 20 min equilibration
period, the arteries were stretched by 100 mm and allowed to equilibrate
for 2 min and tension was recorded using a Myodaq software package
(Danish Myotechnologies, Denmark). The vessels were stretched a further
100 mm and the procedure was repeated in at least three steps until the
passive tension exceeded 5.1 kPa for human placental arteries [vessel
tension expressed as activewall tension (DT inmN/mm) can be transformed
to active effective pressure (DT/(diameter/2000)) denoted by kPa] or
13.3 kPa for human myometrial arteries. Arteries were then normalized to
a resting diameter equivalent to 0.9 of L5.1kPa (placental) or L13.3kPa (myome-
trial) as described previously (Corcoran et al., 2012), and equilibrated in
physiological salt solution (PSS: 127 mM NaCl, 4.7 mM KCl, 2.4 mM
MgSO4 . 7H2O, 25 mM NaHCO3, 1.18 mM KH2PO4, 0.07 mM EDTA,
1.6 mMCaCl2 . 2H2O, 6.05 mM glucose at pH 7.4) at 378C. Myometrial ar-
teries were bubbled with a 95%air–5%CO2 mixture and placental arteries
with 5% O2–5% CO2–90% N2 (Corcoran et al., 2012).
Arteries were preconstricted with 1 mM of the thromboxane receptor
agonist U46619 (9,11-dideoxy-9a,11a-methanoepoxy prostaglandin F2a,
MerckMillipore,UK) and vasoactive actions of estrogenic compounds exam-
inedbyadding incremental doses (5 min durationeach,of 0.05, 0.15, 0.3, 0.6,
1, 2, 5, 10, 30 mM) of either 17b-estradiol, PPT, DPN, G1 or vehicle
(ethanol). The range of doses was chosen to be akin to that reported in
studies on other vessel types (Shaw et al., 2000; Montgomery et al., 2003;
Hisamoto and Bender, 2005; Scott et al., 2007). In some experiments, the
role of the endothelium was investigated by abrading the arterial lumen to
render the endothelium dysfunctional or preincubating with the NOS inhibi-
tor L-NNA (10 mM). Arteries were subsequently constricted with 1 mM
U46619 and cumulative dose–response curves to estrogenic compounds
assessed. Endothelial functional integrity, determined by the relaxant
actions of 1 mMbradykinin onU46619 preconstrictions inmyometrial arter-
ies, was 81+10% before and 19+12% after abrasion. In another set
of experiments, placental arteries were preincubated with the L-type
Ca2+ channel agonist Bay K8644 (1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-
[trifluoromethyl]phenyl)pyridine-3-carboxylic acid methyl ester), further
constrictedwith U46619 and the effects of 17b-estradiol or DPNexamined.
In a subset of experiments, arteries were treated with a-toxin so as to
render the plasmalemma permeable to small solutes and ions and enable
direct investigation of the Ca2+-sensitivity of contraction by directly control-
ling the levelof activatingCa2+ surrounding themyofilaments.Theprocedure
followed was as reported previously (Wareing et al., 2005; Dordea et al.,
2013). In brief, intact PSS-equilibrated vessels were exposed to amock intra-
cellular solution (G1: sodium creatine phosphate 10 mM; Na2ATP 5.2 mM;
magnesium methanesulphonate 7.3 mM; potassium methane sulphonate,
74 mM; K2EGTA 1 mM buffered to pH 7.1 with 30 mM of the chemical
buffer PIPES and addition of KOH) for 15 min and then treated with a
25 ml droplet of permeabilizing cocktail [pCa 6.7 solution (see below) sup-
plemented with 500 U/ml a-toxin plus 10 mmol/l A23187] for 30 min.
The cocktail was removed by washing the vessels with G1 solution followed
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by equilibration of the permeabilized arteries in pCa9 (relaxing) solution
([Ca2+]i ¼ 0.001 mM; sodium creatine phosphate, 10 mM; Na2ATP,
5.2 mM;magnesiummethane sulfonate, 7.3 mM,potassiummethane sulfon-
ate, 74 mM; K2EGTA 1 mM; PIPES, 30 mM; pH 7.1 with KOH). Permeabil-
ization was assessed by exposing vessels to a high calcium activating
solution (pCa4.5 ([Ca2+]i ¼ 31.5 mM)) followedby relaxationwithpCa9 so-
lution. Vessels were exposed to a sub-maximal calcium activating solution
(pCa6.7 ([Ca2+]i ¼ 0.2 mM)) and thence U46619 (1 mM) in the continued
presence of pCa6.7 solution. Any additional constriction was thus due to
sensitization of the contractile filaments to the sub-maximal activating
Ca2+ by the presence of U46619. The experiment was completed by ex-
posure to a maximal dose (30 mM) of either 17-b estradiol or DPN to
examine any effect of these drugs on agonist-dependent Ca2+-sensitization
of contraction.
Data recorded (Myodaq; Danish Myotechnologies, Denmark) as active
wall tension (DT in mN/mm) was transformed to active effective pressure
(DT/(diameter/2000)) denoted by kPa. Data were Arcsine transformed
to enable statistical analysis of dose–response curves by two-way repeated-
measures analysis of variance with Bonferroni post hoc testing (significance
taken as P, 0.05) and presented graphically as mean+ SEM. Emax
(maximal effect) and pIC50 (2Log(IC50)) of drugs were calculated and
effects of endothelial abrasion and NOS inhibition analysed using t-test.
Quantitative polymerase chain reaction
Vessels were homogenized in lysis buffer and total RNA extracted as
described (Dordea et al., 2013). 100 ng RNA from each sample was
reverse transcribed using AffinityScript cDNA synthesis kit (Stratagene,
USA) including a DNase treatment step to eliminate genomic DNA con-
tamination. ERa and ERb were amplified using specific primers (ERa
nm_000125: forward—gct gct ggc tac atc; reverse—agg act cgg tgg ata tgg;
ERb nm_001040275: forward—ata ctt tcc tcc tat gta gac; reverse—tgt gat
aac tgg cga tgg) and quantified using a StratageneMX3000Pmachine and Stra-
tageneBrilliant SYBRGreen IQPCRmastermix. cDNAfromhumanmyome-
trial artery and placental artery samples were assessed on the same 96-well
plate and for each gene of interest data from each sample were expressed
relative to the internal reference cDNA sample [reverse transcribed from
human reference total RNA (Stratagene Human Reference Total RNA, La
Jolla, USA)] also assessed on every 96-well plate and analysed using an inde-
pendent t-test; P, 0.05 was considered significant.
Western blotting
Arteries were homogenized in (1 mg per 5 ml) 50 mM Tris–HCl, 150 mM
NaCl, 1% NP-40, 0.5% Na-deoxycholate, 1 mM EGTA (pH7.4) with 2%
(vol/vol) protease inhibitor and 0.5% (vol/vol) phosphatase inhibitor
(Sigma) and prepared for western blotting as described by Dordea et al.
(2013). Twenty to 30 mg protein from each sample was resolved by SDS–
PAGE and transferred to PVDF membranes for western blotting with anti-
serum against ERb (Abcam #ab288 mouse monoclonal) or ERa (Santa
Cruz Biotechnology #H-184 rabbit polyclonal 1:1000; Santa Cruz Biotech-
nology #MC-20 rabbit polyclonal 1:1000; Vector Labs #VP613 mouse
monoclonal, 1:1000) and membranes visualized chemiluminescently follow-
ing probing with a HRP-goat anti-mouse-IgG (1:5000; DakoCytomation,
#PO447) or HRP-goat anti-rabbit-IgG (1:5000; DakoCytomation, #PO448)
antibody. Theoptical densities from thewestern blot scansweredetermined
using IntelligentQuantifier Software (BioImage Systems Inc.). Protein expres-
sion was quantified by comparing the optical density of the arterial band of
interest to theoptical density of the positive control following the subtraction
of background signal. PVDF membranes were stained with naphthol blue
black in order to visualize actin expression and assess for equal protein
loading between lanes.
Results
17b-estradiol and ER agonists have differing
relaxant actions on humanmyometrial
and placental arteries
17b-estradiol induced significant vasodilation of preconstricted human
myometrial arteries from 0.3 to 30 mM (relaxations to 59+ 5.1%–
0.03+0.03% of preconstriction, Fig. 1A and D). DPN also induced
acute vasodilation from 1 to 30 mM (relaxations to 87+ 3.1%–8.0+
1.0%of preconstriction, Fig. 1B andD) and PPT from2 to 30 mM(relaxa-
tions to 77+ 3.3%–37+ 3.9% of preconstriction, Fig. 1C and D). In
contrast, humanplacental arteries (Fig. 1E–H)exhibited less vasodilation
to 17b-estradiol (from 1 to 30 mM: 76+ 7.1%–42+ 1.1% of precon-
striction; P, 0.001) or DPN (from 2 to 30 mM: 72+ 7.05%–47.6+
6.53% preconstriction; P, 0.006) than myometrial arteries and
showed no relaxation to PPT (Fig. 1G and H). G1 had no relaxant
actions in myometrial or placental arteries (Fig. 1D and H).
Acute relaxatory effects are partly
endothelial- and NO-mediated in human
myometrial arteries but are
endothelial-independent in human placental
arteries
The vasodilatory effects of 17b-estradiol, DPN or PPT on human myo-
metrial arteries were each blunted following endothelial abrasion
(Fig. 2A–C). In endothelial abraded vessels, the relaxation to
17b-oestradiol was 71+4.8%–26+1.8% (0.3–30 mM), to DPN was
49+10%–17+2.3% (2–30 mM) and to PPT was 83+4.5%–57+
4.9% (5–30 mM) of preconstriction. Similar results were obtained in
endothelial-intact arteries exposed to L-NNA (Fig. 2A–C).
The data in Table I shows that either treatment—endothelial abrasion
or preincubation with L-NNA—in myometrial arteries significantly
reduced the maximal relaxation (Emax) induced by each agonist and
mostly resulted in a reduction in sensitivity (pIC50) to each agent.
In contrast to theeffects in intact humanmyometrial arteries, the vaso-
dilatory actions of 17b-estradiol or DPN on human placental arteries
were unaffected by endothelial abrasion (Fig. 3A) or by exposure of
endothelial-intact arteries to L-NNA (Fig. 3B).
Differential expression of ERa and ERb
between humanmyometrial and placental
and arteries
Analysis of ER mRNA demonstrated that both types of artery express
ERa (Fig. 4A) and ERb (Fig. 4B). In myometrial arteries the level of
mRNA encoding ERa (P, 0.01) and ERb (P, 0.04) was greater than
placental arteries. The Ct values of ERa in the myometrial and placental
arteries were, respectively, 24.35+0.11 (n ¼ 6) and 25.43+0.21
(n ¼ 6) (corresponding calibrator RNA 25.43+0.11). The Ct values
of ERb in the myometrial and placental arteries were, respectively,
25.54+0.34 and 25.32+0.02 (corresponding calibrator RNA
28.67+0.15). Western blotting also showed that ERb protein was
greater in myometrial than placental arteries (Fig. 4C and D).
However, in spite of using three separate anti-ERa antibodies (detailed
in the Materials and Methods) we were unable to consistently visualize
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Figure 1 Differential effects of 17b-estradiol and ER agonists on human myometrial and placental arteries. Myometrial (A–D) or placental (E–H)
arteries were preconstricted with U46619 and exposed to incremental doses of estrogenic compounds. Representative raw tracings are displayed in
A–C, E–G, summary data (mean+ SEM, n ¼ 6) in D and H. 17b-estradiol or ERb agonist, DPN relaxed myometrial arteries to a greater extent than
placental arteries whereas ERa agonist, PPT relaxed only myometrial arteries. GPER-1 agonist (G1) was without effect in either artery type. *Significant
differences from time control (TC).
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staining that could be specifically attributable to ERa in myometrial or
placental arteries for the purposes of quantitative comparisons.
Vasodilatory effects of estrogen do not involve
altered Ca21-sensitization of contraction but
are enhanced in the presence of an L-type
Ca21 channel agonist
Figure 5A indicates a representative raw tracing of an a-toxin permeabi-
lized placental artery exhibiting U46619-induced Ca2+-sensitization of
contraction at sub-maximal activating Ca2+ (pCa6.7). This was of
similar magnitude to the preceding contraction induced by maximally
activating pCa4.5 solution. Addition of 30 mM 17b-estradiol was
without effect on this agonist-mediated Ca2+-sensitization (n ¼ 4).
In intact preconstricted placental arteries, the relaxation by
17b-estradiol (B) was enhanced by preincubation with the L-type
Ca2+ channel agonist Bay K8644 (C and D). Similar effects were
observed on DPN-mediated relaxation (D).
Figure 2 Relaxatory actions of estrogenic compounds are partly
endothelial- andNO-dependent in humanmyometrial arteries. The re-
laxation of preconstricted myometrial arteries by 17b-estradiol (A),
PPT (B) or DPN (C) was blunted following endothelial abrasion
(open symbols, dashed lines) or by pretreatment with nitric oxide syn-
thase inhibitor (L-NNA) (open symbols, solid lines). *Significant differ-
ences from intact artery responses. Data are presented as
mean+ SEM (n ¼ 6).
........................................................................................
Table I Effectsof endothelial abrasionorNOS inhibition
on the estrogenic relaxatory responses of human
myometrial arteries.
17b-estradiol PPT DPN
Emax
Intact 0.03+0.03 33.7+4.8 6.9+1.7
Denuded 25.5+5.9a 57.3+4.9a 23.0+2.4a
+LNNA 33.3+3.9a 51.5+2.6a 16.8+2.3a
pIC50
Intact 6.43+0.04 5.42+0.06 5.99+0.04
Denuded 5.47+0.10a 5.17+0.07a 5.48+0.10a
+LNNA 5.34+0.13a 5.14+0.07a 5.84+0.11
The maximum (Emax) and half-maximal (pIC50) relaxation values of preconstricted
myometrial arteries by 17b-estradiol, DPN or PPT.
aSignificant difference from paired intact artery (t-test). Data are presented as mean
+ SEM (n ¼ 6).
Figure 3 Vasodilatory actions of estrogenic compounds are
endothelial-independent in human placental arteries. The relaxation
of preconstricted placental arteries by 17b-estradiol or DPN were un-
altered by endothelial abrasion (A) or by pretreatment with L-NNA
(B). Data are presented as mean+ SEM (n ¼ 6).
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Discussion
Efficient uteroplacental blood perfusion is required for a successful
pregnancy outcome yet the factors and mechanisms involved in con-
trolling vascular tone within the human uterus and placenta are
Figure 4 ER expression in human arteries. Expression of mRNA
encoding for ERa (A) or ERb (B). ERa mRNA expression was greater
in myometrial arteries (MA) than placental arteries (PA). Western blot-
ting indicated that ERexpressionwas greater inmyometrial thanplacental
arteries (C andD). PC, refers to the positive control of human myome-
trium. *Significant differences between MA and PA.
Figure 5 Vasodilatory effects of estrogenic compounds are unrelated
to changes in Ca2+-sensitization of contraction but are enhanced in the
presence of an L-type Ca2+ channel agonist. Permeabilized placental ar-
teries exhibited U46619-induced Ca2+-sensitization of contraction at
sub-maximal activating Ca2+ (pCa6.7) that was similar in magnitude
to contraction in pCa4.5 solution alone (representative raw data tracing
of A). 17b-estradiol (30 mM) did not affect this agonist-mediated
Ca2+-sensitization. In intact preconstricted placental arteries, 17b-
estradiol-mediated relaxation (B) was enhanced by preincubation with
the L-type Ca2+ channel agonist Bay K8644 (C and D). Similar effects
were observed onDPN-mediated relaxation (D). *Significant differences
between 17b-estradiol alone and in the presence of Bay K8644.
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poorly understood. This study is the first to investigate the potential
role of estrogen and estrogen receptors in acutely regulating the vasor-
eactivity of arteries isolated from these circulations at the end of preg-
nancy. Our results demonstrate that the relaxatory influences of
17b-estradiol or ER-specific agonists differ between myometrial and
placental arteries. This suggests that estrogen regulation of humanuter-
oplacental vascular tone occurs in a tissue-specific manner and opens
the possibility that similar variations may occur between other
human vascular beds.
17b-estradiol acutely relaxed preconstricted human myometrial ar-
teries. The ERb-specific agonist DPN and ERa-specific agonist PPT
also exerted vasodilatory effects. The GPER-1 agonist G1 was without
effect. These data point to estrogenic vasodilation of humanmyometrial
arteries via ERb and ERa. In our study, endothelial abrasion, or NOS in-
hibition, resulted in a blunting of relaxatory responses to all three agents
thus indicating that estrogen relaxation of myometrial arteries is
mediated via endothelial-dependent and -independent mechanisms. In
sheep, uterine artery endothelial cells express ERb and ERa and
several estrogenic influences occur in an ER-specific manner (Byers
et al., 2005; Pastore et al., 2012). ERb and ERa have previously been sug-
gested to mediate non-genomic stimulation of NO production (Wu
et al., 2011) and this may underlie the endothelial-dependent relaxant
action of estrogen.
Human placental arteries relaxed to a lesser extent to 17b-estradiol
orDPN thanmyometrial arteries. However, therewas no relaxation to
PPT or G1. Furthermore, the influence of 17b-estradiol or DPN in pla-
cental arteries was unaffected by endothelial abrasion or NOS inhib-
ition. This implicates a prominent role for ERb, but not ERa or
GPER-1, in acute endothelial-independent estrogenic relaxation of
human placental arteries and illustrates profound differences to
human myometrial arteries. The lack of endothelial-dependence in es-
trogen action in placental arteries may be related to a relatively weak
stimulation of NO-mediated relaxation by endothelial-dependent ago-
nists in this vessel type (Sweeney et al., 2008) but is unlikely to be related
to impaired sensitivity of placental artery smooth muscle cells to NO
production (Hayward et al., 2013). In addition, in sheep uterine arterial
endothelial cells the relative expression of endothelial NOS is greater
than that of placental arteries (Byers et al., 2005). The
endothelial-independent mechanisms of actions of estrogen in other
vessels have been suggested to arise via inhibition of voltage-gated
Ca2+ entry to smooth muscle cells (Shaw et al., 2000; Montgomery
et al., 2003). Although in human myometrial and placental arteries
this requires further elucidation we have identified two important
facets of the possible smoothmuscle-relatedmechanismsof estrogenic
action in placental arteries. First, the relaxations are unlikely to involve
the modulation of intracellular pathways affecting myofilament Ca2+-
sensitization. Secondly, that voltage-gated Ca2+ entry is likely to be a
target of acute estrogenic actions because, in the presence of an
L-type Ca2+ channel activator, which one may anticipate to have facili-
tated plasmalemmal Ca2+ entry because contractility is increased, the
vasodilatory estrogenic influences are actually enhanced. Further such
work, in alliance with approaches such as siRNA-mediated receptor
knockdown, or the application of ER-specific antagonists, is needed
to establish whether the tissue-specific responses we observe are
due entirely to ER expression patterns (see below) or the tissue-
specific activation of other post-receptor intracellular signalling modal-
ities. This has recently been suggested, for example, to be important in
these human tissues’ distinct responses to IGF-I or protein kinase G
stimulation (Corcoran et al., 2012; Dordea et al., 2013).
The lack of vasodilatory influence of the GPER-1 agonist G1 on either
artery type was surprising given reports indicating a relaxant action on
human internal mammary artery tone (Hass et al., 2009). This may
reflect tissue-specific actions of G1; however, we investigated the
acute effects (within 5 min of each dose) of G1whereas the vasodilatory
influence onmammary arteries was observed over a longer time-course
(Hass et al., 2009).
Maternal estradiol levels rise continually throughout gestation with
peak values reported to be 60 nM (Norman et al., 1989; O’ Leary
et al., 1991; Smith et al., 2009). Assessments of estradiol in the uterine
orplacental circulations have suggested greater values than in the system-
ic maternal circulationwith peaks of350–500 nM (Smith et al., 1979).
Notwithstanding the possibility that the concentration of estradiol at the
cellular site of action may be greater than that measured in the circula-
tion(s), these in vivo circulating estradiol levels are within the
lower-to-mid-range of our dose–response curves designed to investi-
gate the acute influences on preconstricted tone. A caveat to our
study, of course, is that in vivo the human uterine or placental arteries
will be chronically, rather than acutely, exposed to estrogens.
The differential ER-mediated responses in humanmyometrial and pla-
cental arteries supports a number of animal studies suggesting ER- and
tissue-specific estrogenic vasodilatory actions (Montgomery et al.,
2003; Al Zubair et al., 2005; Bolego et al., 2005; Ma et al., 2010; Patker
et al., 2011). Herein, we found that mRNA encoding ERa and ERb are
present in both artery types. The expression of ERb mRNA or protein
was significantly greater in human myometrial than placental arteries.
In addition, ERamRNAwas greater in myometrial than placental arter-
ies. Of note, the vasodilatory influence of DPN was less in placental ar-
teries than myometrial vessels and PPT was an ineffective relaxant in
placental arteries. ERb has been suggested to be the prominent ER
expressed in endothelial cells of stem villous placental arteries and endo-
metrial uterine vessels (Critchley et al., 2001; Su et al., 2007). These ar-
teries are both downstream of the resistance-like arteries used in the
present study and points, therefore, to a need to consider if there are
functionally relevant ER expression differences across the human
uterine or placental vascular trees. The unreliability (in our hands) of a
number of anti-ERa antibodies to give definitive identification by
western blotting, coupled to the small amount of vascular material avail-
able for extensive optimization procedures, has hampered our ability to
fully examine the ER tissue- and cell-specific protein expression patterns.
Nonetheless, the lack of endothelial-dependence of DPN- or
17b-estradiol-mediated relaxation of placental arteries suggests a pre-
dominating influence of ERb-related events at the level of placental
smooth muscle cells where, indeed, ERb appears to be expressed (Su
et al., 2011). In uterine arteries, on the other hand, the vasodilations
to 17b-estradiol, DPN or PPT involved activation of signalling pathways
in both endothelial and smooth muscle cells.
The present study is important for identifying (i) that estrogen differ-
entially regulates human uterine and placental vascular tone; (ii) the po-
tential of ER-specific agonists to act as tissue-specific modulators of
human uteroplacental vascular tone; (iii) adding to an evolving narrative
in the literaturewhereby circulatory, or locally produced, factorsmaydif-
ferentially alter the tone of human myometrial or placental arteries
(Hemmings et al., 2006; Hudson et al., 2007; Corcoran et al., 2012). It
is of interest that subcutaneous arteries isolated from post-menopausal
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healthy women relaxed more to PPT than 17b-estradiol and the effects
of either agent were unaltered by NOS inhibition (Cruz et al., 2008)—
results that were different to that which we observed in maternal myo-
metrial arteries. These data, therefore, also alerts us to the possibility
that, more generally, estrogenic modulation of human arterial tone
may occur in a tissue-specific manner and thereby contribute to distrib-
uting blood flow in an organ-specific fashion.
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